Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 70Prostatic Neoplasms 66Carcinoma, Non-Small-Cell Lung 65Neoplasms 45Multiple Myeloma 43Lung Neoplasms 37Colorectal Neoplasms 35Melanoma 31Lymphoma, Non-Hodgkin 28Lymphoma 27Leukemia, Myeloid, Acute 27Squamous Cell Carcinoma of Head and Neck 26Pancreatic Neoplasms 26Neoplasm Metastasis 26Ovarian Neoplasms 25Carcinoma, Renal Cell 24Leukemia, Lymphocytic, Chronic, B-Cell 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Endometrial Neoplasms 21Sarcoma 20Carcinoma, Hepatocellular 20Urinary Bladder Neoplasms 19Glioma 19Stomach Neoplasms 18Uterine Cervical Neoplasms 17Recurrence 17Head and Neck Neoplasms 17Rectal Neoplasms 16Lymphoma, Mantle-Cell 16Triple Negative Breast Neoplasms 15

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Respiratory Tract Infections × 30 days × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡